This post is presented by our media partner Cannabis News Wire
View the original article here.
New research has discovered that individuals who use CBD for crack-use disorder may have fewer adverse health events as well as better health outcomes. This is in comparison to patients who were on conventional treatments.
For their study, the researchers conducted a double-blind, randomized, controlled trial where they compared CBD to clonazepam, valproic acid and fluoxetine, which are commonly used to treat crack use disorder. Study participants were 18 to 65 years of age and had either used crack at least 20 times in the last month, used it regularly for the last 12 months, or had an intention or desire to treat their use disorder.
The researchers stated that no considerable differences in reduced crack use were noted between the CBD and control groups. This, they explained, indicated that the treatments were similarly effective. However, they observed that the side effects presented in the CBD group were far gentler than those observed in individuals who were on pharmaceutical therapies. Additionally, the researchers observed no differences between both groups with regard to self-reported crack cravings.
Participants who received CBD treatment also had fewer episodes of constipation, diarrhea, dizziness, nausea, low concentration, ataxia, nasal congestion and memory impairment. The researchers noted that fewer side effects from CBD meant that participants were more likely to continue their treatment. They explained that side effects from conventional treatments were so uncomfortable that they contributed to poor adherence to treatment of individuals with crack use disorder.
A total of 25 individuals completed the study, 10 of whom were in the control group. In their conclusion, the researchers stated that CBD was a tolerable and safe product that alleviated the primary symptoms reported by participants, which included challenges reducing use of crack, lack of appetite and poor health.
The researchers involved in the new study represent official and academic institutions in Brazil, including the Federal University of São Paulo, the Federal District’s secretary of health and forensic institute, and a range of departments at the University of Brasília.
For future studies, the researchers plan to increase their sample sizes in similar trials and also screen and monitor participants more rigorously. This is after 90 of the individuals who were eligible for this trial failed to conclude the full protocol. Additionally, they plan to improve emotional regulation, reduce environmental factors as well as stress and use other cannabinoid options. The research’s findings were reported in the “International Journal of Mental Health and Addiction.”
Cannabis companies, such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), have an opportunity to explore this therapeutic potential of CBD further and assess whether it would be viable to develop products targeting this market segment.
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
This post was originally published by our media partner here.
